HONG KONG, CHINA--(Marketwired - August 09, 2016) - Hutchison China Meditech Limited (NASDAQ: HCM)
Nasdaq: HCM
Director's Share Dealing
London: Tuesday, August 9, 2016: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notification that the spouse of Mr Christopher Nash, Independent Non-executive Director, has purchased 3,120 and 42 ordinary shares of US$1.00 each in Chi-Med (the "Ordinary Shares") at a price of GBP19.00 and GBP18.99 per share respectively on August 4, 2016.
Following the above transaction, the combined holding of Mr Nash and his spouse is 39,596 Ordinary Shares, representing approximately 0.065% of the current issued share capital of Chi-Med.
The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.
----------------------------------------------------------------------------
1 Details of the person discharging managerial responsibilities/person
closely associated
----------------------------------------------------------------------------
a) Name Ms Rebecca Pynt
----------------------------------------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------
a) Position/status Spouse of Mr Christopher Nash, an
Independent Non-executive Director of
Chi-Med
----------------------------------------------------------------------------
b) Initial notification/Amendment Initial notification
----------------------------------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
----------------------------------------------------------------------------
a) Name Hutchison China MediTech Limited
----------------------------------------------------------------------------
b) LEI N/A
----------------------------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type
of instrument; (ii) each type of transaction; (iii) each date; and (iv)
each place where transactions have been conducted
----------------------------------------------------------------------------
a) Description of the financial Ordinary Shares of US$1.00 each DI ISIN:
instrument, type of instrument KYG4672N1016 ADS ISIN: US44842L1035
Identification code
----------------------------------------------------------------------------
b) Nature of the transaction Acquisition of 3,120 and 42 Ordinary
Shares on August 4, 2016 at a price of
GBP19.00 and GBP18.99 respectively
----------------------------------------------------------------------------
c) Price(s) and volume(s)
----------------------------------------
Price(s) Volume(s)
----------------------------------------
GBP19.00 3,120
----------------------------------------
GBP18.99 42
----------------------------------------
----------------------------------------------------------------------------
d) N/A
Aggregated information
-Aggregated volume
-Price
----------------------------------------------------------------------------
e) Date of the transaction 2016-08-04
----------------------------------------------------------------------------
f) Place of the transaction London Stock Exchange (XLON)
----------------------------------------------------------------------------
NOTES TO EDITORS
About Chi-Med
Chi-Med is an innovative China-based biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.
Contacts
Investor Enquiries
Christian Hogg,
CEO +852 2121 8200
International Media
Enquiries
Anthony Carlisle,
Citigate Dewe +44 7973 611 888
Rogerson (Mobile) anthony.carlisle@cdrconsultancy.co.uk
U.S. Based Media
Enquiries
Brad Miles, +1 (917) 570 7340
BMC Communications (Mobile) bmiles@bmccommunications.com
Susan Duffy, +1 (917) 499 8887
BMC Communications (Mobile) sduffy@bmccommunications.com
Investor Relations
Brian Korb, +1 (917) 653 5122
The Trout Group (Mobile) bkorb@troutgroup.com
David Dible,
Citigate Dewe +44 7967 566 919
Rogerson (Mobile) david.dible@citigatedr.co.uk
Panmure Gordon (UK)
Limited
Richard Gray /
Andrew Potts +44 (20) 7886 2500
